Rani Therapeutics Holdings RANI 深 沪
等待开盘 07-21 09:30:00 美东时间
0.4156
-0.001
-0.31%
华盛通- 最 高0.4264
- 今 开0.4168
- 成交量 107.83万股
- 最 低 0.405
- 昨 收 0.4169
- 总市值 1395.18万
- 52周最高 3.75
- 市盈率 静 --
- 换手率 3.21%
- 52周最低 0.387
- 委 比 89.21%
- 总股本 3357.03万
- 历史最高 36.27
- 量 比 0.07
- 振 幅 5.13%
- 历史最低 0.387
- 每 手 1
- 风险率 0.78%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Rani Therapeutics Announces New Securities Purchase Agreement
Rani Therapeutics Holdings ( ($RANI) ) has issued an announcement. On July 14, ...
07-17 02:27
Rani Therapeutics Holdings, Inc. Announces Pricing of $3.0 Million Registered Direct Offering
Rani Therapeutics has entered into a securities purchase agreement with a single institutional investor to sell 4,354,000 shares of its Class A common stock at $0.40 per share and pre-funded warrants for 3,146,000 shares at $0.3999. Maxim Group LLC is acting as the sole placement agent. The offering is expected to close on July 16, 2025, with gross proceeds of approximately $3.0 million. The securities are being offered under a "shelf" registrati...
07-15 13:00
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Sonnet BioTherapeutics (NASDAQ:SONN) shares rose 239.4% to $17.55 dur...
07-14 20:08
Rani Therapeutics Unveils Data on Robotic Pill That Matches Injections in Canine Study at ENDO 2025
Rani Therapeutics Holdings, Inc. ("Rani Therapeutics" or "Rani") (NASDAQ:RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it will present
07-14 17:02
Rani Therapeutics and ProGen Announce Late Breaking Presentation at ENDO 2025 Demonstrating Bioequivalence of Novel, Bispecific GLP-1/GLP-2 Receptor Agonist Delivered Orally via RaniPill Compared to Subcutaneous Delivery
Rani Therapeutics will present preclinical data on its RaniPill® capsule at the Endocrine Society’s Annual Meeting (ENDO 2025) in San Francisco. The presentation, titled "Oral Delivery of a Bispecific GLP-1/GLP-2 Receptor Agonist (PG-102) via a Robotic Pill (RT-114) Achieves Bioequivalence to Subcutaneous Injection in Canines," will be a poster presentation on July 14 from 12:00 PM to 1:30 PM PT. Rani Therapeutics, a clinical-stage biotherapeutic...
07-14 09:00
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Tiziana Life Sciences (NASDAQ:TLSA) shares increased by 10.2% to $1.51...
05-23 05:05
Rani Therapeutics Secures $4.3M via Series D Warrant
The latest announcement is out from Rani Therapeutics Holdings ( ($RANI) ). On ...
05-20 21:17
美股大行评级 | 潜在涨幅2840.31%！Mersana Therapeutics获Truist Securities升目标价至10美元，维持"买入"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1130419824951111681.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Truist Securities：维持Mersana Therapeutics(MRSN)"买入"评级，目标价从9美元升至10美元</p> <p>• Guggenheim：维持Cabaletta Bio(CABA)"买入
05-17 08:44
Oppenheimer Maintains Outperform on Rani Therapeutics Hldgs, Lowers Price Target to $4
Oppenheimer analyst Andreas Argyrides maintains Rani Therapeutics Hldgs (NASDAQ:RANI) with a Outperform and lowers the price target from $14 to $4.
05-17 01:33
